What the FDA labels say about taking them together
Ranitidine and risperidone
Risperidone's FDA label of May 28, 2026 names ranitidine in its drug interactions section; the ranitidine label PlainMeds reads does not name risperidone. The risperidone label: “Concomitant use with methylphenidate, when there is change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS).”
Check it at the source: the ranitidine FDA label on DailyMed (effective May 1, 2026, Amneal Pharmaceuticals of New York LLC); the risperidone FDA label on DailyMed (effective May 28, 2026, Janssen Pharmaceuticals, Inc.).
What does the ranitidine label say about risperidone?
Ranitidine's label (effective May 1, 2026) does not name risperidone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Ranitidine), Amneal Pharmaceuticals of New York LLC, effective May 1, 2026 (SPL set b38a3332-5c54-453f-aeb7-070f830955c2), via openFDA; the full label on DailyMed
What does the risperidone label say about ranitidine?
Risperidone label, drug interactionsDose adjustment is not recommended for RISPERDAL when co-administered with ranitidine, cimetidine, amitriptyline, or erythromycin [see Table 18 ].
Risperdal Consta label (Janssen Pharmaceuticals, Inc., November 5, 2025), drug interactionsAvoid alcohol. ( 7.1 ) Due to hypotensive effects, hypotensive effects of other drugs with this potential may be enhanced. ( 7.2 ) Effects of levodopa and dopamine agonists may be antagonized. ( 7.3 ) Cimetidine and ranitidine increase the bioavailability of risperidone. ( 7.5 ) Clozapine may decrease clearance of risperidone. ( 7.7 ) Fluoxetine and paroxetine increase plasma concentrations of risperidone. ( 7.12 ) Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone.
Rykindo Extended-Release Microspheres label (Shandong Luye Pharmaceutical Co., Ltd., May 26, 2026), drug interactionsClinical Impact: Concomitant use with methylphenidate, when there is change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS). … dosage adjustment of RYKINDO ® is required when administered concomitantly with amitriptyline, cimetidine, ranitidine, clozapine, topiramate and moderate CYP3A4 inhibitors (erythromycin). Additionally, no dosage adjustment is necessary for lithium, valproate, topiramate, digoxin and CYP2D6 substrates …
Source: FDA drug label (Risperdal Consta, NDA021346), Janssen Pharmaceuticals, Inc., effective November 5, 2025 (SPL set bb34ee82-d2c2-43b8-ba21-2825c0954691), via openFDA
Source: FDA drug label (Rykindo Extended-Release Microspheres, NDA212849), Shandong Luye Pharmaceutical Co., Ltd., effective May 26, 2026 (SPL set 58534c96-96f5-4c2e-a061-92d4506aee91), via openFDA
Source: FDA drug label (Risperidone, NDA020588), Janssen Pharmaceuticals, Inc., effective August 20, 2026 (SPL set 701e1cd8-2868-4d29-85a9-a2212c88165f), via openFDA
Source: FDA drug label (RISPERDAL), Janssen Pharmaceuticals, Inc., effective May 28, 2026 (SPL set 7e117c7e-02fc-4343-92a1-230061dfc5e0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ranitidine | Risperidone | |
|---|---|---|
| Labeled for | Acid reflux and ulcers | Bipolar disorder, Schizophrenia |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.0368 per tablet 0.25 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once